Regeneron Pharmaceuticals has appealed a court decision that allowed Amgen to proceed with the sale of its biosimilar version of Eylea, a blockbuster drug for eye conditions. The move comes after Regeneron failed to secure a preliminary injunction to block Amgen’s biosimilar, Pavblu, from entering the market.